Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853115 | 0.84 | GRM5 (0.38) | GRM5CYP3A4MAPTLMNACA12 | |
| SCHEMBL12004228 | 0.83 | FFAR1 (0.48) | GRM5CYP3A4CA12CA1CA2 | |
| SCHEMBL1751529 | 0.83 | GFER (0.50) | GRM5GFERCA12CA1CA2 | |
| SCHEMBL1661500 | 0.82 | RXFP1 (0.44) | GRM5CYP3A4MAPTLMNA | |
| SCHEMBL853262 | 0.82 | GRM5 (0.53) | GRM5 | |
| SCHEMBL854291 | 0.82 | GRM5 (0.54) | GRM5CYP3A4MAPT | |
| SCHEMBL2433672 | 0.81 | APP (0.45) | GRM5MAPTLMNA | |
| SCHEMBL18180530 | 0.81 | FFAR1 (0.48) | GRM5CYP3A4CA12CA1CA2 | |
| SCHEMBL853918 | 0.81 | FFAR1 (0.51) | GRM5CA12CA1CA2CA9 | |
| SCHEMBL852513 | 0.80 | GAA (0.50) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1226108-A4 | DIARYL-ENYNES | NPS ALLELIX CORP (CA) | 2004-06-16 | — | — | EP | disclosed |
| US-6579987-B2 | Reducing an ester containing ene-yne conjugated, silane and aryl or heteroaryl functionality to an alcohol; bromination, amination, desilanation, coupling and deprotecting | NPS ALLELIX CORPORATION (CA) | 2003-06-17 | — | — | US | disclosed |
| US-20030092769-A1 | DIARYL-ENYNES | NPS ALLELIX CORPORATION (CA) | 2003-05-15 | — | — | US | disclosed |
| US-6525085-B2 | Treating neurological and neuropsychiatric disorders | NPS ALLELIX CORP. (CA) | 2003-02-25 | — | — | US | disclosed |
| US-20020169197-A1 | Diaryl-enynes | NPS ALLELIX CORP. | 2002-11-14 | — | — | US | disclosed |
| EP-1226108-A1 | DIARYL-ENYNES | NPS Allelix Corp. (CA) | 2002-07-31 | — | — | EP | disclosed |
| US-6426364-B1 | NERVOUS SYSTEM OR PSYCHOLOGICAL DISORDERS | NPS ALLELIX CORP. (CA) | 2002-07-30 | — | — | US | disclosed |
| WO-2001032602-A1 | DIARYL-ENYNES | NPS ALLELIX CORP. (CA) | 2001-05-10 | — | — | WO | disclosed |
| US-4105854-A | PROSTAGLANDINS, VETERINARY MEDICINE, LUTEOLYSIS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169197-A1 | Diaryl-enynes | CBR3, CNR1, NR3C2 | GRM5 1813/4885CYP3A4 1996/4885MAPT 4189/4885 |
| US-20030092769-A1 | DIARYL-ENYNES | CBR3, CNR1, CBR1 | GRM5 1818/4885CYP3A4 2069/4885MAPT 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.